The most important indication for the PD-L1 testing in melanoma patients comes from the results of the CheckMate067 study, a phase 3 trial comparing Nivolumab and Ipilimumab alone or combined in advanced melanoma patients [72]. This evidence concerns the gene CD274 and melanoma.